The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP

Cardiovascular Research

Volumn 107, Issue 4, 2015, Pages 546-555

  McKean, Jenny S ^a   Murray, Fiona ^a   Gibson, George ^b   Shewan, Derryck A ^a   Tucker, Steven J ^a   Nixon, Graeme F ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

cAMP; Epac; Migration; Prostacyclin; Vascular smooth muscle cell

Indexed keywords

ANTIPORTER; BERAPROST; CYCLIC AMP; CYCLIC AMP BINDING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR BB; RAP1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROSTACYCLIN;

ACTIN FILAMENT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOSKELETON; EX VIVO STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAPHENOUS VEIN; SENSOR; VASCULAR SMOOTH MUSCLE CELL; ANALOGS AND DERIVATIVES; CELL CULTURE; CELL MOTION; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EPOPROSTENOL; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION;

EID: 84948130256     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv176     Document Type: Article

References (32)

1. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2012; 100:3-9.
2. Owens CD. Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications. J Vasc Surg 2010;51:736-746.
3. Garg S, Bourantas C, SerruysPW. New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol 2013;10:248-260.
4. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007; 100:607-621.
5. Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 2004;14:241-249.
6. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614-624.
7. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001;11: 471-477.
8. Nakayama M, Amano M, Katsumi A, Kaneko T, Kawabata S, Takefuji M, Kaibuchi K. Rho-kinase and myosin II activities are required for cell type and environment specific migration. Genes Cells 2005;10:107-117.
9. Liu B, Itoh H, Louie O, Kubota K, Kent KC. The signaling protein Rho is necessary for vascular smooth muscle migration and survival but not for proliferation. Surgery 2002; 132:317-325.
10. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22: 32-39.
11. Palmer D, Tsoi K, Maurice DH. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 1998; 82:852-861.
12. Seiji K, Tsuda M, Matsuhashi T, Takase K, Miyachi H, Yamada T, Ishibashi T, Higano S, Takahashi S. Treatment of in-stent restenosis with beraprost sodium: an experimental study of short-And intermediate-Term effects in dogs. Clin Exp Pharmacol Physiol 2009; 36:1164-1169.
13. Harada M, Toki Y, Numaguchi Y, Osanai H, Ito T, Okumura K, Hayakawa T. Prostacyclin synthase gene transfer inhibits neointimal formation in rat balloon-injured arteries without bleeding complications. Cardiovasc Res 1999;43:481-491.
14. Fetalvero KM, Martin KA, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2007;82:109-118.
15. Marzoll A, Nagy N, Wordehoff L, Dai G, Fries S, Lindner V, Grosser T, Fischer JW. Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening. J Cell Mol Med 2009;13:3713-3719.
16. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396:474-477.
17. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem 2000;275: 20829-20836.
18. Chrzanowska-Wodnicka M. Distinct functions for Rap1 signaling in vascular morphogenesis and dysfunction. Exp Cell Res 2013;319:2350-2359.
19. Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, Insel PA. The cyclic AMP effector Epac integrates pro-And anti-fibrotic signals. Proc Natl Acad Sci USA 2008;105: 6386-6391.
20. Chrzanowska-Wodnicka M, Kraus AE, Gale D, White GC, Vansluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood 2008;111:2647-2656.
21. Zieba BJ, Artamonov MV, Jin L, Momotani K, Ho R, Franke AS, Neppl RL, Stevenson AS, Khromov AS, Chrzanowska-Wodnicka M, Somlyo AV. The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by downregulation of RhoA activity. J Biol Chem 2011;286:16681-16692.
22. Roberts OL, Kamishima T, Barrett-Jolley R, Quayle JM, Dart C. Exchange protein activated by cAMP (Epac) induces vascular relaxation by activating Ca2+-sensitive K+ channels in rat mesenteric artery. J Physiol 2013;591:5107-5123.
23. Hewer RC, Sala-Newby GB, Wu YJ, Newby AC, Bond M. PKA and Epac synergistically inhibit smooth muscle cell proliferation. J Mol Cell Cardiol 2011;50:87-98.
24. Hunter I, Mascall KS, Ramos JW, Nixon GF. A phospholipase Cg1-Activated pathway regulates transcription in human vascular smooth muscle cells. Cardiovasc Res 2011; 90:557-564.
25. Murray AJ, Tucker ST, Shewan DA. cAMP-dependent axon guidance is distinctly regulated by Epac and protein kinase A. J Neurosci 2009;29:15434-15444.
26. Hunter I, Cobban HJ, Vandenabeele P, MacEwan DJ, Nixon GF. Tumor necrosis factor-Alpha-induced activation of RhoA in airway smooth muscle cells: role in the Ca2+ sensitization of myosin light chain20 phosphorylation. Mol Pharmacol 2003;63: 714-721.
27. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62:107-133.
28. Mayer P, Hinze AV, Harst A, von Kugelgen I. A?B receptors mediate the induction of early genes and inhibition of arterial smooth muscle cell proliferation via Epac. Cardiovasc Res 2011;90:148-156.
29. Yokoyama U, Minamisawa S, Quan H, Akaike T, Jin M, Otsu K, Ulucan C, Wang X, Baljinnyam E, Takaoka M, Sata M, Ishikawa Y. Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration. Am J Physiol Heart Circ Physiol 2008;295:H1547-H1555.
30. Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M. Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. Arterioscler Thromb Vasc Biol 2014;34:1486-1494.
31. Vachiery JL. Prostacyclins in pulmonary arterial hypertension: the need for earlier treatment. Adv Ther 2011;28:251-269.
32. Ishihara T, Hayashi E, Yamamoto S, Kobayashi C, Tamura Y, Sawazaki R, Tamura F, Tahara K, Kasahara T, Ishihara T, Takenaga M, Fukuda K, Mizushima T. Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. J Control Release 2015;197:97-104.